Patients diagnosed with end-stage renal disease (ESRD) demonstrate very high cardiovascular pathologies mediated by traditional cardiovascular risk factors as well as abnormal mineral metabolism and a state of chronic inflammation. Sevelamer is a nonabsorbable non–calcium-based hydrogel with potential anti-atherosclerotic action. The current study elucidated the impact of sevelamer on cardiovascular-related mortality in patients undergoing hemodialysis. This was a cross-sectional study that assessed thirty patients selected based on inclusion and exclusion criteria.  These patients were admitted to the hemodialysis de and the study was conducted in the department of a tertiary hospital in South India from March to August 2022.  Patients’ Serum creatinine, Uric Acid, Phosphate, Low-density lipoprotein, and Carotid Doppler Findings were measured at the interval of 1,3,6 month before and after taking sevelamer.  The use of sevelamer as a calcium-free phosphate binder was associated with the slow progression of vascular calcification, improved survival, and decreased phosphate levels in the serum of hemodialysis patients.

Keywords: Cross-sectional study, Sevelamer, Hemodialysis patient, Low-density Lipoprotein.